KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
11.20
+0.27 (+2.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close10.93
Open10.99
Bid9.70 x 300
Ask13.00 x 1000
Day's Range10.59 - 11.37
52 Week Range5.48 - 15.80
Volume47,252
Avg. Volume69,168
Market Cap120.786M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Business Wire2 months ago

    KalVista Pharmaceuticals Commences Two Clinical Trials

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the initiation of two clinical trials: a Phase 2 proof-of-concept clinical trial evaluating the safety, tolerability, and efficacy of KVD001 as a treatment for diabetic macular edema , as well as a Phase 1 trial ...

  • Business Wire2 months ago

    KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal second quarter ended October 31, 2017.

  • Business Wire3 months ago

    KalVista Pharmaceuticals to Present at Stifel Healthcare Conference

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 15, 2017, at 8:00 a.m.

  • KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check
    Simply Wall St.4 months ago

    KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check

    KalVista Pharmaceuticals Inc (NASDAQ:KALV) is a small-cap stock with a market capitalization of USD $99.96M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • ACCESSWIRE4 months ago

    KalVista, Notable Investment and Collaboration Agreement

    NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • American City Business Journals4 months ago

    ​Merck takes stake in small Cambridge rare disease biotech, lifting shares

    KalVista Pharmaceuticals, a small Cambridge biotech with a pair of rare disease treatments in early-stage studies, saw its market value soar on Tuesday after announcing that drug giant Merck has taken ...

  • Capital Cube4 months ago

    ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to KalVista Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to KALV-US. Comparing the performance and risk of KalVista Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Company News For Oct 11, 2017
    Zacks4 months ago

    Company News For Oct 11, 2017

    Companies in the news are: CUDA,MRK,ANAB,HDSN

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.

    NEW YORK, NY / ACCESSWIRE / October 11, 2017 / U.S. major indexes continued to hit new record highs Tuesday as consumer staples were lifted by Wal-Mart Stores Inc.'s announcement of a $20 billion share ...

  • Small-Cap Biotech Rockets After Dow's Merck Buys 10% Stake
    Investor's Business Daily4 months ago

    Small-Cap Biotech Rockets After Dow's Merck Buys 10% Stake

    KalVista shot to a 16-month high Tuesday after it inked a deal with Merck for its eye drugs and allowed the Dow component to take a nearly 10% ownership stake.

  • TheStreet.com4 months ago

    KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

    Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.

  • 24/7 Wall St.4 months ago

    KalVista Pharma Wins Big on Merck Collaboration

    KalVista Pharmaceuticals saw its shares absolutely explode early on Tuesday after it was announced that the firm would be collaborating with Merck.

  • Business Wire4 months ago

    KalVista Pharmaceuticals Announces Collaboration with Merck

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for KVD001, the Company’s investigational intravitreal injection candidate currently ...

  • Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?
    Simply Wall St.5 months ago

    Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?

    KalVista Pharmaceuticals Inc (NASDAQ:KALV) announced a loss of -$20.09M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for KALV mayRead More...

  • Capital Cube5 months ago

    ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to KalVista Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to KALV-US. Comparing the performance and risk of KalVista Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire5 months ago

    KalVista Pharmaceuticals Reports Fiscal First Quarter Results

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal first quarter ended July 31, 2017.